LY4170156

Other Medications

Description

LY4170156 is an experimental drug being studied by Eli Lilly and Company. It is currently in Phase 1 clinical trials for advanced solid tumors, including colorectal cancer. Phase 1 trials are primarily designed to assess the safety and tolerability of a new drug in people, determine the best way to give the drug, and find the highest dose that can be given without causing unacceptable side effects. The goal is to see if LY4170156 is safe and potentially effective in patients with advanced colorectal cancer who may have limited treatment options. The trial is currently recruiting participants.

Mechanism of Action

LY4170156 is being investigated as a potential treatment for advanced solid tumors. The specific way it works (its mechanism of action) is still being studied in clinical trials. Researchers are evaluating how it affects cancer cells and the body's response to it.

Side Effects

Because LY4170156 is an experimental drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of the Phase 1 trial is to determine the safety and tolerability of the drug. Information about specific side effects will become clearer as more patients are treated in the trial.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06400472 Phase 1

Recruiting

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

United States, Australia, France, Italy, Japan, South Korea, Spain

Quick Info

Category	Other Medications
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.